Announcements Trials
Browse Landscape Eligibility

Clinical Trials

1 trials
RecentStart dateEnrollment
PFS × Clear all

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 11735Neoplasms 9361Carcinoma, Non-Small-Cell Lung 6100Prostatic Neoplasms 5640Colorectal Neoplasms 5275Lung Neoplasms 4518Multiple Myeloma 3186Pancreatic Neoplasms 3174Neoplasm Metastasis 3120Leukemia, Myeloid, Acute 3104Carcinoma, Hepatocellular 2907Ovarian Neoplasms 2832Melanoma 2805Stomach Neoplasms 2722Lymphoma 2681Head and Neck Neoplasms 2313Recurrence 2268Precursor Cell Lymphoblastic Leukemia-Lymphoma 2207Leukemia 2131Brain Neoplasms 2099Colonic Neoplasms 2065Lymphoma, Non-Hodgkin 2019Rectal Neoplasms 1955Uterine Cervical Neoplasms 1910Glioblastoma 1813Leukemia, Lymphocytic, Chronic, B-Cell 1776Carcinoma, Renal Cell 1700Squamous Cell Carcinoma of Head and Neck 1651Lymphoma, Follicular 1631Esophageal Neoplasms 1603

Interventions

Bevacizumab 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT05267288 2023-03-29

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Qingdao Central Hospital

Phase 2 Unknown
30 enrolled

PFS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡